Synthesis and myorelaxant activity of fused 1,4-dihydropyridines on isolated rabbit gastric fundus

Drug Development Research

Volumn 73, Issue 6, 2012, Pages 332-342

  Şafak, Cihat ^a   Gündüz, Miyase Gözde ^a   Özlhan, Sevil Özger ^b   Şimaşek, Rahime ^a   Iş, Fatma ^b   Yildirim, Şeniz ^b   Fincan, Gökçe Sevim Öztürk ^b   Saraoǧlu, Yusuf ^b   Linden, Anthony ^c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

4 dihydropyridine; calcium channel modulator; condensed 1; myorelaxant activity

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; CALCIUM ANTAGONIST; MUSCLE RELAXANT AGENT; NIFEDIPINE; TETRAHYDROTHIOPHENE 3 ONE 1, 1 DIOXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; NONHUMAN; RABBIT; STOMACH FUNDUS; TREATMENT RESPONSE;

EID: 84866431923     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21024     Document Type: Article

References (21)

1. Altenbach RJ, Kalvoda L, Carroll WA,. 2004. A convenient multigram scale synthesis of tetrahydrothiophene-3-one-1,1-dioxide. Synth Commun 34: 567-570. (Pubitemid 38352375)
2. Coburn RA, Wierzba M, Suto MJ, Solo AJ, Triggle AM, Triggle DJ,. 1988. 1,4-Dihydropyridine antagonist activities at the calcium channel: a quantitative structure-activity relationship approach. J Med Chem 31: 2103-2107.
3. Dolphin AC,. 2006. A short history of voltage-gated calcium channels. Br J Pharmacol 147: 156-162.
4. Edraki N, Mehdipour AR, Khoshneviszadeh M, Miri R,. 2009. Dihydropyridines: evaluation of their current and future pharmacological applications. Drug Discov Today 14: 1058-1066.
5. Gordeev MF, Patel DV, England BP, Jonnalagadda S, Combs JD, Gordon EM,. 1998. Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers. Bioorg Med Chem 6: 883-889. (Pubitemid 28464518)
6. Leonardi A, Motta G, Penninia R, Testab R, Sironi G, Cattoc A, Zappa CM, Bianchif G, Nardig D,. 1998. Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity. Eur J Med Chem 33: 399-420. (Pubitemid 28240092)
7. Linden A, Şafak C, Şimşek R, Gündüz MG,. 2011. Two 1,4-dihydropyridine derivatives with potential calcium-channel antagonist activity. Acta Crystallogr C 67: 80-84.
8. Mehdipour AR, Javidnia K, Hemmateenejad B, Amirghofran Z, Miri R,. 2007. Dihydropyridine derivatives to overcome atypical multidrug resistance: design, synthesis, QSAR studies, and evaluation of their cytotoxic and pharmacological activities. Chem Biol Drug Des 70: 337-346. (Pubitemid 47537694)
9. Miri R, Javidnia K, Sarkarzadeh H, Hemmateenejad B,. 2006. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist. Bioorg Med Chem 14: 4842-4849.
10. Rose U,. 1990. 5-Oxo-1,4-dihydroindenopyridines: calcium modulators with partial calcium antagonistic activity. J Heterocycl Chem 27: 237-242. (Pubitemid 20187652)
11. Şafak C, Şimşek R,. 2006. Fused 1,4-dihydropyridines as potential calcium modulatory compounds. Mini Rev Med Chem 6: 747-755. (Pubitemid 44027727)
12. Şimşek R, Şafak C, Erol K, Ataman Ş, Ülgen M, Linden A,. 2003. Evaluation of the calcium antagonistic activity and biotransformation of hexahydroquinoline and furoquinoline derivatives possessing calcium modulating activity. Arzneimittelforschung 53: 159-166. (Pubitemid 36363611)
13. Şimşek R, Öztürk GS, Vural Ä°M, Gündüz MG, Sarioǧlu Y, Şafak C,. 2008. Synthesis and calcium modulatory activity of 3-alkyloxy-carbonyl-4-(disubstituted)aryl-5-oxo- 1,4,5,6,7,8-hexahydroquinoline derivatives. Arch Pharm 341: 55-60. (Pubitemid 351211814)
14. Sohda T, Momose Y, Meguro K, Kawamatsu Y, Sugiyama Y, Ikeda H,. 1990. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneimittelforschung 40: 37-42. (Pubitemid 20037527)
15. Tamazawa K, Arima H, Kojima T, Isomura Y, Okada M, Fujita S, Furuya T, Takenaka T, Inagaki O, Terai M,. 1986. Stereoselectivity of a potent calcium antagonist, 1-benzyl-3-pyrrolidinyl methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4- dihydropyridine-3,5-dicarboxylate. J Med Chem 29: 2504-2511. (Pubitemid 17211411)
16. Triggle DJ,. 2003. The 1,4-dihydropyridine nucleus: a pharmacophoric template part 1. Actions at ion channels. Mini Rev Med Chem 3: 215-223.
17. Tu S, Miao C, Fang F, Youjian F, Li T, Zhuang Q, Zhang X, Zhu S, Shi D,. 2004. New potential calcium channel modulators: design and synthesis of compounds containing two pyridine, pyrimidine, pyridone, quinoline and acridine units under microwave irradiation. Bioorg Med Chem Lett 14: 1533-1536. (Pubitemid 38299444)
18. Vaghy PL, Williams JS, Schwartz A,. 1987. Receptor pharmacology of calcium entry blocking agents. Am J Cardiol 59: 9A-17A. (Pubitemid 17023332)
19. Vo D, Wolowyk MW, Knaus EE,. 1992. Synthesis and cardioselective beta-adrenergic antagonist activity of quinolyloxypropanolamines. Drug Des Discov 9: 69-78.
20. Zamponi GW,. 1997. Antagonist binding sites of voltage-dependent calcium channels. Drug Dev Res 42: 131-143. (Pubitemid 28243280)
21. Zhou K, Wang X, Zhao Y, Cao Y, Fu Q, Zhang S,. 2011. Synthesis and antihypertensive activity evaluation in spontaneously hypertensive rats of nitrendipine analogues. Med Chem Res 20: 1325-1330.